Form 4: iRhythm Director Kevin O'Boyle Receives RSU Grant

Director Kevin O'Boyle was granted 1,573 restricted stock units as part of iRhythm Holdings' equity compensation program.

Summary

• Director Kevin C. O'Boyle acquired 1,573 restricted stock units (RSUs) on May 27, 2026.
• Each RSU represents a contingent right to receive one share of iRhythm Holdings, Inc. (IRTC) common stock.
• The RSUs vest on the earlier of one year from the grant date or the date of the company's next annual meeting.
• Following this transaction, the director's total beneficial ownership is 3,608 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Standard market risks associated with equity ownership in a publicly traded company.

Future Outlook

The RSUs are subject to standard vesting conditions tied to the passage of time or the next annual shareholder meeting.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure long-term alignment with shareholder value in the medical technology sector.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for mid-cap healthcare and technology companies.
• The vesting schedule aligns with typical annual equity refresh cycles observed in the industry.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation.

Next Steps

• Vesting of the 1,573 RSUs on the earlier of May 27, 2027, or the date of the next annual meeting.

Key Dates

Keywords

iRhythm, IRTC, Director, Equity, RSU, Insider Transaction, SEC Form 4